Effects of imidazoline binding site ligands on the growth and viability of clonal pancreatic β-cells

[1]  C. A. Ramsden,et al.  Affinity isolation of imidazoline binding proteins from rat brain using 5‐amino‐efaroxan as a ligand , 1999, FEBS letters.

[2]  A. Noma,et al.  The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. , 1998, Biochemical and biophysical research communications.

[3]  Dave Kendall,et al.  'Seeing through a glass darkly': casting light on imidazoline 'I' sites. , 1998, Trends in pharmacological sciences.

[4]  M. Shibuya,et al.  Clotrimazole, an Imidazole Antimycotic, Is a Potent Inhibitor of Angiogenesis , 1998, Japanese journal of cancer research : Gann.

[5]  F. Ashcroft,et al.  Phentolamine block of KATP channels is mediated by Kir6.2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D. Reis,et al.  Stimulation of imidazoline receptors inhibits proliferation of human coronary artery vascular smooth muscle cells. , 1997, Hypertension.

[7]  C. A. Ramsden,et al.  Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with sigma receptors. , 1997, European journal of pharmacology.

[8]  G. Bertrand,et al.  Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. , 1997, European journal of pharmacology.

[9]  G. Olmos,et al.  Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain. , 1996, European journal of pharmacology.

[10]  R. Sobecks,et al.  Imidazole antifungals Miconazole and Econazole induce apoptosis in mouse lymphoma and human T cell leukemia cells: regulation by Bcl-2 and potential role of calcium. , 1996, Cell death and differentiation.

[11]  L. Callado,et al.  Increased density of I2-imidazoline receptors in human glioblastomas. , 1996, Neuroreport.

[12]  D. Nutt,et al.  [3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. , 1996, European journal of pharmacology.

[13]  D. Reis,et al.  Imidazoline receptors and agmatine in blood vessels: a novel system inhibiting vascular smooth muscle proliferation. , 1996, The Journal of pharmacology and experimental therapeutics.

[14]  D. V. van Helden,et al.  The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. , 1996, Biochemical and biophysical research communications.

[15]  D. Nutt,et al.  Functional Studies of Specific Imidazoline‐2 Receptor Ligands , 1995, Annals of the New York Academy of Sciences.

[16]  G. Pang,et al.  Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. , 1995, European journal of pharmacology.

[17]  B. de Costa,et al.  Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[18]  J. García-Sevilla,et al.  Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease , 1993, Neuroscience Letters.

[19]  M. Sastre,et al.  Opposite Age‐Dependent Changes of α2A‐Adrenoceptors and Nonadrenoceptor [3H]Idazoxan Binding Sites (I2‐Imidazoline Sites) in the Human Brain: Strong Correlation of I2 with Monoamine Oxidase‐B Sites , 1993, Journal of neurochemistry.

[20]  H. J. Olverman,et al.  [3H]p-aminoclonidine and [3H]idazoxan label different populations of imidazoline sites on rat kidney. , 1993, European journal of pharmacology.

[21]  N. Morgan,et al.  Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non‐adrenoceptor idazoxan binding sites , 1993, British journal of pharmacology.

[22]  W. Bowen,et al.  Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. , 1993, European journal of pharmacology.

[23]  Å. Sjöholm Intracellular signal transduction pathways that control pancreatic β‐cell proliferation , 1992, FEBS letters.

[24]  N. Morgan,et al.  The α2-adrenoceptor antagonist efaroxan modulates K+ATP channels in insulin-secreting cells , 1991 .

[25]  J. Henquin,et al.  Clonidine inhibits ATP‐sensitive K+channels in mouse pancreatic β‐cells , 1991 .

[26]  M. Dunne Block of ATP‐regulated potassium channels by phentolamine and other α‐adrenoceptor antagonists , 1991 .

[27]  N. Morgan,et al.  Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. , 1990, European journal of pharmacology.

[28]  D. Langin,et al.  [3H]Idazoxan binding at non-α2-adrenoceptors in rabbit adipocyte membranes , 1989 .

[29]  G. Molderings IMIDAZOLINE RECEPTORS : BASIC KNOWLEDGE, RECENT ADVANCES AND FUTURE PROSPECTS FOR THERAPY AND DIAGNOSIS , 1997 .

[30]  A. Rémaury,et al.  The insulin-secreting cell line, RINm5F, expresses an alpha-2D adrenoceptor and nonadrenergic idazoxan-binding sites. , 1992, The Journal of pharmacology and experimental therapeutics.

[31]  P. Ernsberger,et al.  A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors , 1992 .

[32]  M. Dunne Block of ATP-regulated potassium channels by phentolamine and other alpha-adrenoceptor antagonists. , 1991, British journal of pharmacology.

[33]  J. Wikberg High affinity binding of idazoxan to a non-catecholaminergic binding site in the central nervous system: description of a putative idazoxan-receptor. , 1989, Pharmacology & toxicology.